Apidra (insulin glulisine) received FDA approval in 2004 [1]. It is a rapid-acting insulin analog used to improve glycemic control in adults and children with diabetes mellitus [1][2].
How quickly does Apidra start working?
Apidra is designed to work rapidly, typically beginning to lower blood glucose levels within 10 to 20 minutes after injection [1]. Its peak effect occurs between 1 and 1.5 hours, and its duration of action is generally 3 to 5 hours [1]. This profile makes it suitable for use before meals to manage postprandial (after-meal) blood sugar spikes [2].
What is the difference between Apidra and other insulins?
Apidra is a "mealtime" or "rapid-acting" insulin, distinct from longer-acting insulins that provide basal (background) insulin coverage [2][3]. Compared to regular human insulin, Apidra is absorbed faster and has a shorter duration of action, allowing for more precise mealtime glucose management [1]. Other rapid-acting insulins include lispro (Humalog) and aspart (NovoLog), each with slight variations in onset, peak, and duration [2][4].
When does Apidra's patent expire?
Patent information for specific drugs can be complex and is subject to change due to various factors, including patent challenges and extensions. For detailed and up-to-date patent expiration information for Apidra and related insulin glulisine products, resources like DrugPatentWatch.com can provide comprehensive data [5].
What are the potential risks or side effects of using Apidra?
Like all insulins, the primary risk associated with Apidra is hypoglycemia (low blood sugar) [1][6]. Other potential side effects can include injection site reactions like redness, swelling, or itching, and lipodystrophy (changes in fat tissue) at the injection site with repeated use [1]. Serious allergic reactions are also possible [1].
Can generic versions of Apidra be available?
The availability of generic or biosimilar versions of insulin products depends on patent expiries and regulatory approvals. Once patents expire and regulatory pathways are met, other manufacturers may be able to produce and market their own versions of insulin glulisine [5].
Who manufactures Apidra?
Apidra is manufactured by Sanofi [7].
What clinical data supported Apidra's FDA approval?
The FDA approval of Apidra was based on clinical trials demonstrating its efficacy and safety in managing blood glucose levels in both Type 1 and Type 2 diabetes patients [1]. These studies compared Apidra to other insulins and assessed its impact on fasting and postprandial glucose control, as well as its safety profile [1].
What are patient considerations for using Apidra?
Patients using Apidra need to carefully monitor their blood glucose levels, understand the timing of their injections relative to meals, and be aware of the signs of hypoglycemia [6]. Proper injection technique and rotation of injection sites are also important to prevent lipodystrophy [1]. It is crucial for patients to discuss their insulin regimen with their healthcare provider to ensure it is appropriate for their individual needs [6].
---
1. FDA. (2004, June 8). FDA approves Apidra for diabetes patients. U.S. Food and Drug Administration.
2. Sanofi. (n.d.). Apidra® (insulin glulisine) injection.
3. Mayo Clinic. (n.d.). Insulin (Injectable) - Uses, Side Effects, Dosage, Interactions, Warnings.
4. Diabetes.co.uk. (n.d.). Insulin Types: Fast-Acting, Short-Acting, Intermediate-Acting, Long-Acting.
5. DrugPatentWatch.com. (n.d.).
6. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Insulin Basics.
7. Sanofi. (n.d.). Our Medicines.